Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on X:
“Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study – European Journal of Cancer.”
Title: Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study
Authors: David O Reilly, Anthony O Grady, Conor Hayes, Laura Piggott, Ruaidhri Keane, Orla Fitzpatrick, Michael Conroy, Nicholas Kruseman Aretz, David Synnott, Rachel Dillon, Gavin P Dowling, Daniel J. Ryan, Emmet O’Brien, Ross Morgan, Oscar Breathnach, Liam Grogan, Patrick Morris, Megan Greally, Minh Yuen Teo, Adrian Murphy, Gillian Ryan, Ian Counihan, Cliona Ryan, Helen Barrett, Ann-Marie O’Shea, Sinead Cuffe, Grzegorz Korpanty, Lisa Prior, Martin P. Barr, Stephen Finn, Cathal O Brien, Sarah McCarron, Rob Cummins, Sinead Toomey, Catriona M. Dowling, Siobhan Glavey, Bryan T Hennessy, Jan Sorensen, Kathleen Bennett, Parthiban Nadarajan, Brendan Doyle, Jarushka Naidooa
More posts featuring Aakash Desai on OncoDaily.